Form 8-K - Current report:
SEC Accession No. 0001824293-24-000143
Filing Date
2024-10-24
Accepted
2024-10-24 08:35:47
Documents
18
Period of Report
2024-10-24
Items
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K val-20241024.htm   iXBRL 8-K 23076
2 EX-99.1 ex991_pressreleasewarrantc.htm EX-99.1 15295
7 GRAPHIC image_0.jpg GRAPHIC 38371
8 GRAPHIC val-20241024_g1.jpg GRAPHIC 16879
9 GRAPHIC val-20241024_g2.jpg GRAPHIC 1656
  Complete submission text file 0001824293-24-000143.txt   264458

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT val-20241024.xsd EX-101.SCH 2047
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT val-20241024_def.xml EX-101.DEF 3313
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT val-20241024_lab.xml EX-101.LAB 24438
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT val-20241024_pre.xml EX-101.PRE 15215
20 EXTRACTED XBRL INSTANCE DOCUMENT val-20241024_htm.xml XML 2820
Mailing Address 2223 AVENIDA DE LA PLAYA SUITE 208 LA JOLLA CA 92037
Business Address 2223 AVENIDA DE LA PLAYA SUITE 208 LA JOLLA CA 92037 (619) 400-1171
GRI BIO, Inc. (Filer) CIK: 0001824293 (see all company filings)

EIN.: 824369909 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40034 | Film No.: 241390829
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)